JP2008543278A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008543278A5 JP2008543278A5 JP2008510449A JP2008510449A JP2008543278A5 JP 2008543278 A5 JP2008543278 A5 JP 2008543278A5 JP 2008510449 A JP2008510449 A JP 2008510449A JP 2008510449 A JP2008510449 A JP 2008510449A JP 2008543278 A5 JP2008543278 A5 JP 2008543278A5
- Authority
- JP
- Japan
- Prior art keywords
- conjugate
- antibody molecule
- conjugate according
- seq
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 102000013462 Interleukin-12 Human genes 0.000 claims description 10
- 108010065805 Interleukin-12 Proteins 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 230000033115 angiogenesis Effects 0.000 claims description 4
- 108010029485 Protein Isoforms Proteins 0.000 claims description 2
- 102000001708 Protein Isoforms Human genes 0.000 claims description 2
- 102000007000 Tenascin Human genes 0.000 claims description 2
- 108010008125 Tenascin Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims 11
- 108020001507 fusion proteins Proteins 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 239000000833 heterodimer Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 1
- 102000016359 Fibronectins Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 210000002744 extracellular matrix Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 206010012689 Diabetic retinopathy Diseases 0.000 description 4
- 206010064930 age-related macular degeneration Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 201000011066 hemangioma Diseases 0.000 description 4
- 208000002780 macular degeneration Diseases 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68010505P | 2005-05-11 | 2005-05-11 | |
| PCT/EP2006/004114 WO2006119897A2 (en) | 2005-05-11 | 2006-05-03 | Fusion protein of antibody l19 against fibronectin ed-b and interleukin 12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008543278A JP2008543278A (ja) | 2008-12-04 |
| JP2008543278A5 true JP2008543278A5 (enExample) | 2009-05-07 |
Family
ID=37027526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008510449A Pending JP2008543278A (ja) | 2005-05-11 | 2006-05-03 | フィブロネクチンｅｄ−ｂに対する抗体ｌ１９とインターロイキン１２との融合タンパク質 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8455625B2 (enExample) |
| EP (1) | EP1891102B1 (enExample) |
| JP (1) | JP2008543278A (enExample) |
| KR (1) | KR101281208B1 (enExample) |
| CN (1) | CN101258162A (enExample) |
| AT (1) | ATE459648T1 (enExample) |
| AU (1) | AU2006246061A1 (enExample) |
| BR (1) | BRPI0609100A2 (enExample) |
| CA (1) | CA2607954A1 (enExample) |
| DE (1) | DE602006012667D1 (enExample) |
| EA (1) | EA011992B1 (enExample) |
| ES (1) | ES2341126T3 (enExample) |
| MX (1) | MX2007013875A (enExample) |
| WO (1) | WO2006119897A2 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
| DE10324447A1 (de) | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin |
| ES2606490T3 (es) * | 2006-05-08 | 2017-03-24 | Philogen S.P.A. | Citocinas dirigidas por anticuerpos para terapia |
| EP1925664A1 (en) | 2006-11-15 | 2008-05-28 | Scil proteins GmbH | Artificial binding proteins based on a modified alpha helical region of ubiquitin |
| EP2653478B1 (en) | 2007-04-02 | 2016-10-05 | Philogen S.p.A. | A novel antigen associated with the neovasculature of tumour metastases |
| US10202442B2 (en) | 2007-07-25 | 2019-02-12 | Philogen S.P.A. | Antigen associated with lung cancers and lymphomas |
| CN101918443B (zh) * | 2007-10-30 | 2013-07-17 | 菲洛根股份公司 | 一种与类风湿性关节炎相关的抗原 |
| US8697081B2 (en) | 2008-04-09 | 2014-04-15 | The Regents Of The University Of Michigan | Method of modulating neovascularization |
| CA2747154C (en) | 2008-12-19 | 2015-11-10 | Philogen S.P.A. | Immunocytokines for tumour therapy with chemotherapeutic agents |
| US8679488B2 (en) | 2009-08-05 | 2014-03-25 | Philogen S.P.A. | Targeting of bone marrow neovasculature |
| MX2012002014A (es) * | 2009-08-17 | 2012-06-13 | Roche Glycart Ag | Inmunoconjugados dirigidos. |
| RU2556820C2 (ru) | 2009-12-14 | 2015-07-20 | Сцил Протеинс Гмбх | Модифицированные убиквитиновые белки со специфической связывающей активностью для экстрадомена "в" фибронектина |
| WO2012001196A2 (es) | 2010-06-28 | 2012-01-05 | Proyecto De Biomedicina Cima, S.L. | Vectores alfavirales y usos de los mismos para la expresión de genes heterólogos |
| RU2429005C1 (ru) * | 2010-10-07 | 2011-09-20 | Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН | Способ стимуляции противоопухолевой активности цитотоксических эффекторов иммунной системы |
| US9266938B2 (en) * | 2011-02-10 | 2016-02-23 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
| EP2672999A2 (en) | 2011-02-10 | 2013-12-18 | Roche Glycart AG | Improved immunotherapy |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| WO2012171541A1 (en) | 2011-06-15 | 2012-12-20 | Scil Proteins Gmbh | Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins |
| JP6146821B2 (ja) | 2011-06-15 | 2017-06-14 | ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ | 修飾ユビキチンに基づく二量体型結合タンパク質 |
| EP2736535B1 (en) | 2011-07-27 | 2018-10-17 | Philogen S.p.A. | Il-12 immunoconjugate |
| US10195253B2 (en) * | 2011-09-26 | 2019-02-05 | Philogen S.P.A. | Immunocytokine combination therapy |
| WO2013186329A1 (en) | 2012-06-13 | 2013-12-19 | Scil Proteins Gmbh | Human fusion proteins comprising single chain tnfalpha and targeting domains |
| ES2743423T3 (es) | 2012-10-03 | 2020-02-19 | Philogen Spa | Conjugado de anticuerpos para su uso en el tratamiento de una enfermedad inflamatoria intestinal |
| WO2014094799A1 (en) | 2012-12-19 | 2014-06-26 | Scil-Proteins-Gmbh | Ubiquitin moieties as a means for prolonging serum half-life |
| WO2014182532A1 (en) | 2013-05-07 | 2014-11-13 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Mesothelin-specific immunocytokine and use thereof |
| SG11201604781RA (en) * | 2013-12-18 | 2016-07-28 | Intrexon Corp | Single chain il-12 nucleic acids, polypeptids, and uses thereof |
| GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| JP6738340B2 (ja) | 2015-02-06 | 2020-08-12 | ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ | 新規なｅｇｆｒ結合タンパク質 |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| EP3322721B1 (en) | 2015-07-16 | 2021-12-08 | Navigo Proteins Gmbh | Novel immunoglobulin-binding proteins and their use in affinity purification |
| EP3322719B1 (en) | 2015-07-16 | 2019-12-18 | Philogen S.p.A. | Il22 immunoconjugates |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| JP2018520675A (ja) | 2015-07-20 | 2018-08-02 | ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ | ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法 |
| GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
| GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
| AU2017260274A1 (en) | 2016-05-04 | 2018-11-01 | Navigo Proteins Gmbh | Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker |
| CA3031955A1 (en) | 2016-07-29 | 2018-02-01 | Juno Therapeutics, Inc. | Immunomodulatory polypeptides and related compositions and methods |
| JP6951417B2 (ja) | 2016-08-11 | 2021-10-20 | レプリゲン・コーポレイションＲｅｐｌｉｇｅｎ Ｃｏｒｐｏｒａｔｉｏｎ | アフィニティークロマトグラフィーのためのＦＣ−結合タンパク質、並びにＦｃ−結合タンパク質を含むアフィニティー分離マトリックスおよびその使用 |
| HUE070615T2 (hu) * | 2016-10-17 | 2025-06-28 | Pfizer | Anti-EDB antitestek és antitest-gyógyszer konjugátumok |
| GB201621806D0 (en) | 2016-12-21 | 2017-02-01 | Philogen Spa | Immunocytokines with progressive activation mechanism |
| CN108250302A (zh) * | 2016-12-29 | 2018-07-06 | 天津天锐生物科技有限公司 | 一种多功能蛋白质 |
| EP3648786A4 (en) | 2017-07-03 | 2021-12-15 | Torque Therapeutics, Inc. | FUSION MOLECULES TARGETING IMMUNE REGULATORY CELLS AND THEIR USES |
| EP3706804B1 (en) | 2017-11-07 | 2022-02-23 | Navigo Proteins GmbH | Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer |
| TWI844524B (zh) | 2018-02-09 | 2024-06-11 | 義大利商費洛根公司 | 靶向edb之il-12組合物 |
| KR102140557B1 (ko) * | 2018-03-30 | 2020-08-03 | 한국과학기술원 | 단백질-단백질 결합체를 형성 매개 펩타이드 및 이를 이용한 단백질-단백질 결합체 형성 방법 |
| WO2020047473A1 (en) * | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
| KR20250160211A (ko) | 2018-08-30 | 2025-11-11 | 이뮤니티바이오, 인크. | 다중-사슬 키메라 폴리펩타이드 및 이의 용도 |
| CN113365663B (zh) | 2018-08-30 | 2025-11-21 | 免疫生物公司 | 单链嵌合多肽和其用途 |
| WO2020070150A1 (en) | 2018-10-02 | 2020-04-09 | Philogen S.P.A | Il2 immunoconjugates |
| EP3660039A1 (en) | 2018-11-30 | 2020-06-03 | Philogen S.p.A. | Il2 immunoconjugates |
| AU2019409572B2 (en) | 2018-12-18 | 2022-11-24 | Navigo Proteins Gmbh | Novel FOLR1 specific binding proteins for cancer diagnosis and treatment |
| US20220118015A1 (en) * | 2019-02-01 | 2022-04-21 | Board Of Regents, The University Of Texas System | Modified il-12 t cell therapy for the treatment of cancer |
| CA3127985A1 (en) | 2019-02-04 | 2020-08-13 | University Of Tartu | Bi-specific extracellular matrix binding peptides and methods of use thereof |
| CN111848811B (zh) * | 2019-04-27 | 2024-10-01 | 张晋宇 | 一种蛋白质异二聚体及其用途 |
| WO2020249757A1 (en) | 2019-06-14 | 2020-12-17 | Philogen S.P.A | Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha |
| AU2020294797B2 (en) | 2019-06-21 | 2025-12-18 | Immunitybio, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| JP2023513573A (ja) | 2020-02-11 | 2023-03-31 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 加齢性および炎症性疾患を治療する方法 |
| AU2021219720B2 (en) | 2020-02-11 | 2025-10-02 | Immunitybio, Inc. | Chromatography resin and uses thereof |
| CA3169243A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| WO2021209452A1 (en) * | 2020-04-14 | 2021-10-21 | Philogen S.P.A. | Dosage units and regimen, uses, methods or formulations of compositions comprising a recombinant protein comprising interleukin-12 and an antibody binding the extra-domain b of fibronectin |
| US12497462B2 (en) | 2020-04-29 | 2025-12-16 | Immunitybio, Inc. | Anti-CD26 proteins and uses thereof |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| US20230399371A1 (en) * | 2020-10-29 | 2023-12-14 | Proviva Therapeutics (Hong Kong) Limited | Il-12 compositions and methods of use thereof |
| JP7690131B2 (ja) | 2022-01-04 | 2025-06-09 | フィロジェン ソチエタ ペル アツィオーニ | Ｉｌ－１２を含むイムノサイトカインとキナーゼ阻害剤の組合せ |
| WO2024052333A1 (en) | 2022-09-06 | 2024-03-14 | Philochem Ag | Multivalent fibroblast activation protein ligands for targeted delivery applications |
| WO2026003203A1 (en) | 2024-06-27 | 2026-01-02 | Philogen S.P.A. | Combination of an immunocytokine comprising targeted il2 and a jak inhibitor |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2221717T3 (es) * | 1997-12-08 | 2005-01-01 | Emd Lexigen Research Center Corp. | Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general. |
-
2006
- 2006-05-03 ES ES06742774T patent/ES2341126T3/es active Active
- 2006-05-03 JP JP2008510449A patent/JP2008543278A/ja active Pending
- 2006-05-03 MX MX2007013875A patent/MX2007013875A/es active IP Right Grant
- 2006-05-03 EP EP06742774A patent/EP1891102B1/en active Active
- 2006-05-03 AU AU2006246061A patent/AU2006246061A1/en not_active Abandoned
- 2006-05-03 CA CA002607954A patent/CA2607954A1/en not_active Abandoned
- 2006-05-03 CN CNA2006800158042A patent/CN101258162A/zh active Pending
- 2006-05-03 BR BRPI0609100-8A patent/BRPI0609100A2/pt not_active IP Right Cessation
- 2006-05-03 WO PCT/EP2006/004114 patent/WO2006119897A2/en not_active Ceased
- 2006-05-03 US US11/913,483 patent/US8455625B2/en not_active Expired - Fee Related
- 2006-05-03 KR KR1020077028774A patent/KR101281208B1/ko not_active Expired - Fee Related
- 2006-05-03 EA EA200702460A patent/EA011992B1/ru not_active IP Right Cessation
- 2006-05-03 DE DE602006012667T patent/DE602006012667D1/de active Active
- 2006-05-03 AT AT06742774T patent/ATE459648T1/de active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008543278A5 (enExample) | ||
| KR101281208B1 (ko) | 피브로넥틴 ｅｄ-ｂ에 대한 항체 ｌ１９ 및 인터루킨１２의 융합 단백질 | |
| Holz et al. | A review of protein-and peptide-based chemical conjugates: past, present, and future | |
| Shipunova et al. | Versatile platform for nanoparticle surface bioengineering based on SiO2-binding peptide and proteinaceous Barnase* Barstar interface | |
| US20240277863A1 (en) | Antibody-urease conjugates for therapeutic purposes | |
| WO2000056774A1 (en) | Methods of using bioelastomers | |
| CA3062962C (en) | Multispecific protein drug and library thereof, preparing method therefor and application thereof | |
| JP2010519182A (ja) | 多量体接合体 | |
| Grigoletto et al. | The evolution of polymer conjugation and drug targeting for the delivery of proteins and bioactive molecules | |
| AU2020366846A1 (en) | Humanized antibody and method for using the same | |
| Nanaware-Kharade et al. | Therapeutic anti-methamphetamine antibody fragment-nanoparticle conjugates: synthesis and in vitro characterization | |
| CN101249262A (zh) | 人源化单克隆抗体Trastuzumab修饰的包裹毒素蛋白的靶向纳米粒及其制备与应用 | |
| KR102019407B1 (ko) | 타겟분자를 선택적으로 포획하는 덱스트란 고분자 기반의 증폭된 핵산 압타머 나노구조체의 제조방법 | |
| CN105247047A (zh) | 抗体-尿素酶偶联物在诊断和治疗中的应用 | |
| HK40117905A (zh) | 用於治疗目的的抗体-脲酶缀合物 | |
| HK40089788A (zh) | 纳米脂蛋白-多肽缀合物和组合物、系统以及其使用方法 | |
| HK1238557A1 (en) | Antibody-urease conjugates for therapeutic purposes | |
| HK1113579B (en) | Fusion protein of antibody l19 against fibronectin ed-b and interleukin 12 |